
On my way home from San Francisco, I checked my Function Health results. My PSA was 5.0, higher than the usual cut-off of 4. Only 10% of it was floating free in the blood, and the report wanted more than 25%. The clinician note called it "a red flag." I'm a doctor, so I knew PSA can change for harmless reasons. I still made an appointment with a urologist.
This episode follows that result from the lab report to the MRI, and checks the numbers along the way. It starts with why men wait: the rectal exam many dread, and a pattern I call information loses to incentives. Your Tuesday meeting has a calendar invite. Your prostate doesn't. Germany's 2025 guideline says doctors should not use the finger exam for early detection, yet public insurance still pays for the finger exam from 45 and not for the PSA test.
Then the evidence. The largest European trial invited men aged 55 to 69 to regular PSA tests and followed them for 23 years: one death from prostate cancer prevented for every 456 men invited, with 12 extra men diagnosed for each death prevented. A Swedish study found that men in the top tenth of PSA at age 45 to 49 accounted for 44% of later prostate cancer deaths. And in one American study, about 4 out of 10 men with a high PSA had a normal result at one or more later yearly checkups.
The 25% free-PSA cutoff comes from a 1998 study of men aged 50 to 75 with a PSA between 4 and 10, nearly half of whom had cancer. With 25% as the line, 95 out of 100 men with cancer fell below it, and so did about 80 out of 100 men whose biopsies were normal. My Berlin lab uses 15% for the same ratio.
Along the way: the strongest case against screening, from Germany's evidence institute IQWiG, and what a British trial showed when doctors watched instead of treating.
The episode closes with how I chose between an MRI and micro-ultrasound, what the one large trial of micro-ultrasound showed, what my MRI found, my verdicts, and three things you can do today.
In this episode:
- Why men wait, and the exam that's on its way out as a screening test.
- Germany's mismatch: insurance pays for the finger exam, not the PSA test.
- Screening saves lives, slowly: one death prevented for every 456 men invited.
- One PSA at 45 tells you a lot.
- A high PSA is a question: size, inflammation, ejaculation and finasteride.
- Where the 25% free-PSA cutoff comes from, and who was in the study.
- MRI or micro-ultrasound: I chose by calendar.
- What my MRI found, in three words of German.
- My verdicts, and three things to do today.
Visit The Upward ARC and subscribe.
Under Load is the Sunday edition of The Upward ARC, by Andre Heeg, MD, DDS, doctor and dentist, trained in facial surgery. This edition sits within the Capacity pillar: what helps you carry the load at 50 and at 70.
This episode is general health education, not individual medical advice. If your PSA is high, or you're not sure when to start testing, talk to your doctor.
Key sources
- Leitlinienprogramm Onkologie, 2025: S3-Leitlinie Prostatakarzinom, Kurzversion 8.1.
- Prostate Cancer Foundation of Australia, 2026: 2026 guidelines for the early detection of prostate cancer in Australia.
- Cornford et al., 2026: EAU guidelines on prostate cancer (March 2026 update).
- Gemeinsamer Bundesausschuss, 2025: Früherkennung von Prostatakrebs: G-BA prüft risikoabhängiges Angebot.
- Roobol et al., 2025: European study of prostate cancer screening: 23-year follow-up.
- Hamdy et al., 2023: Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer.
- IQWiG, 2026: Risikoadaptiertes PSA- und MRT-Screening, Vorbericht S25-02.
- Vickers et al., 2013: PSA at age 40-55 and long-term risk of metastasis.
- Lin et al., 2026: Updates to early detection of prostate cancer: AUA/SUO guideline (2026).
- Nadler et al., 1995: Effect of inflammation and benign prostatic hyperplasia on elevated serum PSA levels.
- Tchetgen et al., 1996: Ejaculation increases the serum prostate-specific antigen concentration.
- D'Amico & Roehrborn, 2007: Effect of 1 mg/day finasteride on serum PSA in men with androgenic alopecia.
- Eastham et al., 2003: Variation of serum PSA levels: year-to-year fluctuations.
- Catalona et al., 1998: Use of the percentage of free PSA to differentiate prostate cancer from benign prostatic disease.
- Kinnaird et al., 2025: Microultrasonography-guided vs MRI-guided biopsy: the OPTIMUM randomized clinical trial.
- Kasivisvanathan et al., 2018: MRI-targeted or standard biopsy for prostate-cancer diagnosis (PRECISION).
Weitere Episoden von „Under Load“



Verpasse keine Episode von “Under Load” und abonniere ihn in der kostenlosen GetPodcast App.








